5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 30.58▼ | 30.47▲ | 30.43▲ | 28.78▲ | 28.50▲ |
MA10 | 30.56▲ | 30.38▲ | 29.98▲ | 27.98▲ | 31.30▼ |
MA20 | 30.50▲ | 29.83▲ | 29.27▲ | 28.21▲ | 31.22▼ |
MA50 | 30.35▲ | 28.86▲ | 28.28▲ | 31.84▼ | 28.67▲ |
MA100 | 30.00▲ | 28.17▲ | 27.73▲ | 31.30▼ | 28.19▲ |
MA200 | 29.29▲ | 27.68▲ | 29.76▲ | 29.47▲ | 27.50▲ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.005▲ | 0.009▲ | 0.133▲ | 0.464▲ | -0.684▼ |
RSI | 54.864▲ | 65.534▲ | 68.887▲ | 57.996▲ | 50.766▲ |
STOCH | 74.164 | 58.280 | 69.703 | 85.474▲ | 24.988 |
WILL %R | -56.667 | -26.212 | -24.497▲ | -14.741▲ | -53.903 |
CCI | 129.451▲ | 53.890 | 77.712 | 260.467▲ | -56.476 |
Thursday, May 01, 2025 01:32 PM
Alkermes has a huge opportunity to expand its label to include pediatric patients with Schizophrenia and bipolar I disorder. Click to read my ALKS analysis.
|
Thursday, May 01, 2025 08:21 AM
Discover Alkermes' Q1 2025 insights: impressive revenue growth, LYBALVI sales up 23%, and progress in the ALKS 2680 program.
|
Tuesday, April 29, 2025 04:59 PM
Check Out Our Latest Stock Analysis on Alkermes Alkermes Stock Performance Shares of NASDAQ:ALKS opened at $28.77 on Wednesday. The firm has a market cap of $4.74 billion, a price-to-earnings ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
01/05/25 | 28.73 | 31.32 | 28.54 | 30.58 | 2,935,392 |
30/04/25 | 28.97 | 28.97 | 28.31 | 28.77 | 2,422,953 |
29/04/25 | 27.80 | 28.875 | 27.80 | 28.78 | 1,564,355 |
28/04/25 | 27.93 | 28.28 | 27.61 | 27.91 | 1,517,299 |
25/04/25 | 27.53 | 27.875 | 27.315 | 27.84 | 1,206,315 |
24/04/25 | 27.24 | 27.95 | 27.005 | 27.67 | 1,968,723 |
23/04/25 | 27.69 | 27.88 | 26.86 | 27.15 | 1,790,760 |
22/04/25 | 27.33 | 27.60 | 26.81 | 27.11 | 1,967,143 |
21/04/25 | 26.99 | 27.80 | 26.70 | 27.00 | 1,864,754 |
17/04/25 | 27.05 | 27.52 | 26.98 | 27.00 | 1,699,443 |
|
|
||||
|
|
||||
|
|